Ogd2 Pharma

Université De Nantes

Activen

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Nantes Université

Institut De Cancerologie De L'ouest

Jean-Marc Le Doussal

Mylene Dorvillius

Mickael Terme

Denis Cochonneau

Brigitte Assouline

Stephane Birkle

Louis Lamy

Reto Stocklin

Bethsabee Coutaz

Mickaël Terme

Stéphane Birkle

Sébastien Faraj

Julien Fleurence

Mylène Dorvillius

Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.

Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs

Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.

Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2)

An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.

Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy forcancer

A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1&#x3b3;1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1&#x3b3;1 domain by the CH1 domain from a human IgG2 (CH1&#x3b3;2), IgG3 (CH1&#x3b3;3) or IgG4 (CH1&#x3b3;4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (&#x3ba;)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.

Human IgG1 derived antibody with pro-apoptotic activity

Antibody which binds to the O-acetylated-GD2 ganglioside, includes: a) a light chain including three light chain complementary regions (CDRs) having the following amino acid sequences: CDR1: QSLLKNNGNTFL (SEQ id no 1), CDR2: KVS, CDR3: SQSTHIPYT (SEQ id no 2); and a light chain framework sequence from an immunoglobulin light chain, including the human kappa (&#x3ba;)CL domain; and b) a heavy chain including three heavy chain complementary regions (CDRs) having the following amino acid sequences: CDR1: EFTFTDYY (SEQ id no 3), CDR2: IRNRANGYTT (SEQ id no 4), CDR3: ARVSNWAFDY (SEQ id no 5), and a heavy chain framework sequence from an immunoglobulin heavy chain, including CH2 and CH3 domains from a human IgG1, and a CH1 domain from a human IgG1, which is mutated to restore pairing between CH1 and light chain that is typical of other human IgG subclasses or substituted by a CH1 domain from such non-IgG1 subclasses as human IgG2, IgG3 or IgG4.

Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity

A cosmetic composition containing as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide is provided. In particular, a composition wherein the mu-conotoxin peptide is Arginine, lysine polypeptide (INCI name: pyroglutamyl s-mu-conotoxin CnIIIc amide acetate), CAS Number: 937286-43-6 (renumbered 936616-33-0), Molecular formula C,H,N,O,Sacetate salt (molar mass 2376 g/mol.) is provided. The composition can be used to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Cosmetic composition comprising a muconopeptide

Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer

A cosmetic composition including as an active substance a cosmetically effective amount of at least one mu-conotoxin peptide It further concerns a composition wherein the mu-conotoxin peptide is Argninine, lysine polypeptide, CAS Number: 937286-43-6, Molecular formula C,H,N,O,Sacetate salt (molar mass 2376 g/mol.). Also, the use of the composition to improve the mechanical properties of the skin, tonicity and/or firmness and/or elasticity of the skin.

Growing community of inventors

Lausanne, Switzerland

Jean-Marc Le Doussal